Journey Medical signals positive EBITDA for remainder of 2026 as it plans to add up to 5 sales professionals (NASDAQ:DERM)
· seekingalpha.com
Journey Medical (DERM) Q1 2026 earnings call: Emrosi growth, PBM/GPO access gains, and path to positive EBITDA.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...